Loading...
•
Sep 30, 2022
UroGen Q3 2022 Earnings Report
UroGen reported financial results for Q3 2022, with JELMYTO® net product revenue increasing by 41% year-over-year and FDA authorization received for an extended in-use period of JELMYTO® admixture.
Key Takeaways
UroGen Pharma reported its Q3 2022 financial results, highlighting a 41% increase in JELMYTO® net product revenue compared to the same period last year, reaching $16.1 million. The FDA authorized an extension of the in-use period for JELMYTO® admixture, and the company is progressing with its UGN-102 Phase 3 pivotal trial.
JELMYTO® net product revenue reached $16.1 million, a 41% increase year-over-year.
FDA authorized an extension of the in-use period for JELMYTO® admixture from 8 to 96 hours.
Full enrollment of ENVISION Phase 3 pivotal trial with UGN-102 expected by the end of November 2022.
NDA submission for UGN-102 anticipated in the first half of 2024.
Revenue by Segment
Forward Guidance
UroGen is focused on advancing its pipeline, particularly UGN-102, and maintaining a disciplined approach to capital preservation.
Positive Outlook
- Expected completion of ENVISION Phase 3 trial enrollment by the end of November 2022.
- Potential for UGN-102 to transform bladder cancer treatment.
- Advancing UGN-301 in a Phase 1 clinical trial.
- FDA authorization to extend JELMYTO’s in-use period for the admixture from 8 hours to 96 hours.
- Favorable growth trends in JELMYTO's net product revenues.
Challenges Ahead
- Clinical trial enrollment challenges may impact the expected timing of planned clinical trials.
- Potential safety and other complications in clinical trials.
- Risk of not obtaining regulatory approval within the expected timeframe or at all.
- Complications associated with commercialization activities, including those resulting from the ongoing COVID-19 pandemic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...